Male Sprague-Dawley rats (8-12 weeks of age; 200-250g; Harlan, Bicester, UK) were euthanized with CO 2 in accordance with guidelines contained within the UK Animals (Scientific Procedures) Act of 1986 and approved by the Queen's University of Belfast Animal Welfare and Ethical Review Body.
Reverse transcription polymerase chain reaction
Retinal homogenates were transferred to a glass-bottomed recording chamber on the stage of an inverted microscope (Nikon Eclipse, TE2000) and retinal arterioles collected using fine tungsten wire slips. Total RNA was extracted using an RNeasy Micro kit (Qiagen, Crawley, UK) according to the manufacturer's instructions. First strand complementary DNA (cDNA) was synthesised using Sensiscript Reverse Transcription kit (Qiagen). The cDNA reverse transcription products were amplified with TRPM4, TRPM7, TRPP1 (PKD2) and TRPV4 specific primers ( Supplementary Table S1 ) by RT-PCR using HotStar Taq reagents (Qiagen). PCR products were resolved on 2% agarose gels. All PCRs included no-reverse transcriptase controls. Total RNA was also extracted from rat kidney to serve as a positive control for amplicons that could not be detected from retinal arterioles. All RT-PCR experiments were repeated using RNA extracted from at least three different animals.
Immunohistochemistry
Immunohistochemistry was carried out on retinal arterioles embedded within retinal wholemount preparations. Posterior eyecups were fixed with 4% paraformaldehyde for 20 minutes and then washed extensively in phosphate buffered saline (PBS) for 4 hours. Retinas were subsequently detached and incubated overnight in permeabilisation and blocking buffer (0.5% Triton X-100 and 1% donkey serum in PBS; Sigma, Poole, Dorset, UK, and Millipore, Watford, UK, respectively) and then incubated in primary antibody in permeabilisation and blocking buffer for 3 days at 4°C. Primary antibodies, selected on the basis of their selectivity towards rat TRP channels ( Supplementary Table S2 ) were employed in conjunction with goat anti--smooth muscle actin (SMA) antibody (1:200; ab21027; Abcam, Cambridge UK) to positively identify arteriolar smooth muscle cells. Following extensive washing (4 hours at 21°C in PBS), 1:200 dilutions of donkey anti-rabbit IgG labelled with Alexa-488 and donkey anti-goat IgG labelled with Alexa-568 (Life Technologies, Paisley UK) were used for TRP channel and arteriolar smooth muscle cell detection, respectively (incubated at 4°C overnight). Nuclei were labelled with the far-red nuclear stain TOPRO3 (1:1000; Life Technologies; pseudo-coloured blue in relevant images). In one set of experiments, wholemount preparations were co-labelled with isolectin B4 and SMA to identify arteriolar smooth muscle cell membranes. 1 For detection of isolectin binding, isolectin B4 from Bandeiraea simplicifolia (1mg/ml; biotin conjugate; Sigma) followed by Alexa Fluor-488 Streptavidin (Life Technologies) was used. Images were acquired using a Leica SP5 confocal laser scanning microscope (Leica Geosystems; Heerbrugg, Switzerland; HCX PL APO x63 oil immersion lens) equipped with Argon, HeNe 543 and HeNe 633 lasers. Each fluorescent channel was excited and captured sequentially to minimise bleed-through. Images were taken at a plane of focus where any immunostaining of astrocytic projections was only observed in regions surrounding the vessels and not overlapping areas of SMA expression. Following acquisition, images were digitally segmented using the SMA channel in order to isolate retinal arterioles from the surrounding retinal neuropile. All secondary-only controls were negative for staining.
Intracellular Ca 2+ recording
Isolated retinal arterioles were incubated in the dark at room temperature in low Ca 2+ Hanks' solution containing 5M Fura 2-AM (Abcam) for 2 hours. We have previously shown that when added externally Fura-2 loading is restricted to the smooth muscle layer of these vessels. 2 They were then washed and superfused with Hanks' solution (140mM NaCl, 6mM KCl, 5mM D-glucose, 2mM CaCl 2 , 1.3mM MgCl 2 , 10mM HEPES; pH 7.4 with NaOH) at 37°C in a perfusion bath mounted on the stage of an inverted microscope (Nikon Eclipse TE2000). Arterioles were alternately illuminated by 340/380 nm light via an oil immersion UV objective (x100, NA 1.3. Nikon) using a vibrating monochromator (5 Hz, 10nm bandwidth; Optoscan; Cairn Research Ltd., Faversham, UK). Emitted fluorescence was measured from the side port of the microscope via an adjustable rectangular window, a filter (510 nm) and a photon counting photomultiplier tube (PMT) in the light path. Fluorescence equipment was controlled by Acquisition Engine (Cairn) software (V1.1.5) which was also used for storage and analysis of the fluorescence data. At the end of each experiment, background fluorescence was measured following Fura-2 quenching by incubating the cells with 10 mM MnCl 2 in Ca 2+ free Hanks' solution (140mM NaCl, 6mM KCl, 5mM D-glucose, 1.3mM MgCl 2 ; 10mM HEPES; pH set to 7.4 with NaOH). Background-corrected fluorescence ratios (R-F340/F380) were converted to intracellular Ca 2+ ([Ca 2+ ] i ) using the Grynkiewicz equation. 3 Drugs were delivered via a gravity-fed multi-channel perfusion manifold connected to a single outlet needle that was positioned adjacent to the vessel of interest. To reduce the possible contribution of swell-activated Clcurrents to hypotonic stretch-induced responses internal Clwas depleted prior to recording by the application of 10mM caffeine (10 seconds duration, repeated every 2 minutes a total of 5 times) in isotonic low Clexternal solution (Solution A1, Supplementary Table S3 ; osmolarity 296.8 ± 2.5 mOsm). We have previously shown that this protocol depletes internal Clas indicated by a loss of inward Ca 2+ -activated Clcurrents in arteriolar VSMCs. 4 To stretch cells hypotonic solution (low Clisotonic solution with the mannitol concentration reduced by 100 mM; Solution A2, Supplementary Table S3 ; 197.8 ± 4.3 mOsm) was applied for 2 minutes and changes in [Ca 2+ ] i recorded. Zero Ca 2+ hypotonic solution (0Ca 2+ o ) was of the same composition as the normal hypotonic external solution (Solution A2, Supplementary Table S3 ) but with no added Ca 2+ and 10 µM EGTA. With the exception of experiments using anti-TRPC1 blocking antibody and the TRPP1/TRPV2 inhibitor, amiloride 5 , TRP channel inhibitors were applied 30 seconds after hypotonic stretch-induced [Ca 2+ ] i rises had reached steady-state levels. For inhibition of TRPC1, arterioles from individual animals were divided into two aliquots, one of which was exposed to the externally acting, anti-TRPC1 blocking antibody, T1E3 (1:200) 6 , and the other exposed to an anti-TRPC1 antibody targeting an internal epitope of the channel (ACC-010; Alomone, Israel; 1:200 anti-TRPC1 control antibody) for 2 hours at 21°C. Hypotonic stretch-induced [Ca 2+ ] i responses were then compared between the two groups of vessels and a third group of unexposed (control) vessels. Addition of the TRPP1/V2 inhibitor amiloride resulted in a small, but rapid drop in the resting R340/380 ratio caused by the inherent fluorescence of this compound 7 which was more prominent at the 380nm excitation wavelength. This complicated the accurate measurement of the effects of this drug when applied during steady-state hypotonicity-induced [Ca 2+ ] i responses. To circumvent this, we adopted an alternative experimental protocol whereby arterioles were exposed to two applications of hypotonic solution (2 minutes 30 seconds apart), first in the absence and then in the presence of amiloride. After the initial hypotonicity-induced [Ca 2+ ] i response, the vessel was returned to isotonic conditions for 2 minutes and then pre-incubated with amiloride for 30 seconds prior to a second application of hypotonic medium in the continued presence of the drug. The amplitude of the second response was then compared to the first. In timematched control experiments in the absence of amiloride, consecutive applications of hypotonic solution produced [Ca 2+ ] i responses that did not differ significantly from one another ( Supplementary Fig S1 below) . For graphical representation, all changes in [Ca 2+ ] i are normalised to the mean control ∆[Ca 2+ ] i .
Patch-clamp recording
In situ electrophysiological recordings from retinal arteriolar smooth muscle cells were performed using the whole-cell (perforated patch) and cell-attached configurations of the patch-clamp technique applied to arteriolar segments. Isolated arterioles were placed in a glass-bottomed recording bath on the stage of an inverted microscope (Nikon Eclipse TE300) and anchored down using tungsten wire slips. They were then digested 'in bath' with protease type XIV (0.01 mg/ml, 10 minutes; Sigma), collagenase 1A (0.1 mg/ml, 10 minutes; Sigma), and DNAse I (0.02 mg/ml, 5 minutes; Millipore) in low Ca 2+ Hanks' solution at 37ºC to remove surface basal lamina, electrically uncouple the arteriolar smooth muscle cells from one another and the underlying endothelium, and to remove extraneous DNA. 8, 9 Ionic currents were recorded using an Axopatch 200B patch-clamp amplifier (Molecular Devices, CA, USA). Data acquisition and analysis was performed using pCLAMP software (Version 10.2). Internal (pipette) and external solution compositions are listed in Supplementary Table S3 . To isolate stretch-activated cation currents, inhibitors of BK channels (100nM Penitrem A 9 ), K v channels (10mM 4-aminopyridine 9 ), L-type Ca 2+ channels (10M nimodipine 10 ) and TREK-1 channels (100M fluoxetine 11 ) were included in the external bathing medium (whole-cell recordings) or internal pipette solution (cell-attached recordings).
For whole-cell recording, pipettes with a tip resistance of 1-2MΩ were pulled from filamented borosilicate glass capillaries (Harvard Instruments, Kent UK). Amphotericin B was included in the pipette solutions to perforate the membrane ( Supplementary Table S3 ). Signals were sampled at 20kHz and low-pass filtered at 2kHz. Liquid junction potentials ( Supplementary  Table S3 ), cell capacitance (11.7  1.3 pF) and series resistance were routinely compensated and only recordings with stable series resistances <15M were included in the study. Whole-cell currents were elicited by ramp protocols from -80 to +80 mV applied over 1 second from a holding potential of 0 mV. Current amplitudes at -80 and +80mV were measured offline. Current densities were calculated by dividing current amplitudes by the whole-cell capacitance. External solutions were applied using a gravity-driven perfusion system with an exchange time of approximately 1 second. 2 For hypotonic stretch-activated current measurements, possible contributions of swell-activated Clconductances were minimised through the replacement of Clions in the extracellular and pipette solutions with D-Gluconic Acid ( Supplementary Table S3 , solutions A1-4 and A5 respectively).
For cell-attached recordings, pipettes with tip resistances of 3-5MΩ were used. Currents were sampled at 20kHz and low-pass filtered at 5kHz. After formation of a G seal, pipette capacitance was compensated using the nulling circuitry of the patch-clamp amplifier. Recordings were performed in high K + solution in order to set the resting membrane potential of the cells close to 0mV. Liquid junction potentials were negligible (<1 mV; Supplementary Table S3 ) and therefore were not compensated. In order to minimise any contribution from Clchannels, stretch-activated current activity was monitored at a potential of +52mV, to correspond with the predicted reversal potential for Clions under our recording conditions (E Cl =+52.3 mV based on the [Cl -] i of 46 mM 4 ). The reversal potential for currents carried by TRPV2 (E rev(TRPV2) ) was estimated to be 0.5 mV as calculated using the known permeability properties of the channels 12 and the Goldman-Hodgkin-Katz voltage equation. 13 To stretch the membrane at the pipette tip, negative pressure was applied to the recording pipette by a syringe that was connected to a custom-built digital manometer. Stretchactivated cation current activity was integrated and the computed net charge movement (in picoColoumbs, pC) per second of recording used for statistical comparisons.
Arteriolar Pressure Myography
Arterioles were harvested and transferred to a perfusion chamber on the stage of an inverted microscope (Nikon Eclipse TE2000). One end of the vessel was occluded using a tungsten wire slip and the open end cannulated using a glass micropipette (tip diameter 3-10 µm) filled with Ca 2+ free Hanks' solution. Following introduction of the pipette, the vessel was superfused with normal Hanks' solution for 10-15 min, allowing the pipette to seal to the inner vessel wall. Vessels were then pressurised to 40 mmHg and left at that pressure for 15 mins to enable the development of myogenic tone. Intraluminal pressure was regulated by using a manometer connected to the cannulating micropipette (Riester "Big Ben" pressure manometer; Riester, Jungingen, Germany). Vessels were viewed under a 20x, NA 0.4 objective and images (saved as BMP images of 1280×1024 pixels; 8-bit; 1.2 MB) captured at a rate of 140 images per minute using a MCN-B013-U USB camera (Mightex, Pleasanton, CA, USA). Image acquisition was carried out using custom software implemented in Delphi.
The measurement of vessel diameters and tracking of diameter changes was performed using MyoTracker software. 14 Arteriole diameters were normalised to the maximum (passive) diameter measured following application of wortmannin (10μM; myosin light chain kinase inhibitor) in the presence of Ca 2+ -free Hanks' solution at the end of the experiment. 15 
Chemicals, drugs and antibodies
TRP channel inhibitors used were as follows: FTY720 (TRPM7 16 ; Sigma); amiloride (TRPP1/V2 5, 17 ; Sigma); capsazepine (TRPV1 18 ; Tocris, Bristol UK); tranilast (TRPV2 19, 20 ) ; LKT Laboratories Inc. Minnesota USA) and HC067047 (TRPV4 21 Tocris). Penitrem A, fluoxetine and the TRPV2 activator, delta-9-tetrahydrocannabinol (Δ9THC 22 ), were purchased from Tocris. Nimodipine, 4-aminopyridine and caffeine were from Sigma. HEPES and Mannitol were obtained from Melford Laboratories Ltd (Ipswich, UK). Unless otherwise stated, all other chemicals were purchased from Sigma. TRPV2 pore-blocking antibody was obtained from Alomone Labs (ACC039) 23 , while the TRPV2 negative control antibody targeting an intracellular epitope of the channel was purchased from Millipore (PC421). Both antibodies were used at a dilution of 1:100 for the patch clamp and arteriolar myography studies.
Statistical Analyses
All data are presented as means  SEM. Values of n refer to the number of arterioles for the Ca 2+ recording and pressure myography experiments or the number of cells for the patchclamp studies. Data from at least four animals was acquired for each experimental protocol. Where data conformed to Kolmogorov-Smirnov normality tests, paired or unpaired Student's t-tests were used. In cases where data did not meet the requirements for parametric analysis, the Wilcoxon matched-pairs signed rank test or Mann Whitney U tests were performed. Multiple group data were checked for normality and analysed using repeated measures ANOVA with Dunnett's post hoc test or Kruskal-Wallis one-way ANOVAs with Dunns post-hoc test. All statistical analyses were carried out on the raw data and the 95% level was accepted as statistically significant. Statistical comparisons were carried out using Excel or Prism 5 for Windows (version 5.03; GraphPad Software Inc., La Jolla, CA, USA). In all graphical representations of the data, statistical significance is indicated as follows: NS, P>0.05; *=P<0.05; **=P<0.01; ***=P<0.001. Figure S1 : Repeated applications of hypotonic solution ( Supplementary Table S3, 
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